Next, I don't think you are the only one who would be buying more shares, in both companies actually, if Don was replaced at CEO by someone with real biotech credentials and a track record of biotech success. Perhaps some removals and replacements on both boards as well. I do hope we have the opportunity to ask questions in some form at the AGM (Oct 28), the rationale/reason for what would seem to be heavily discounted financing is at the top of my list.